Advertisement

Clinical update on the use of recombinant factor VII

  • Steven Glazer
  • Ulla Hedner
  • Jorn F. Falch
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)

Abstract

Much effort has converged on finding an agent capable of activating the final common pathway of the coagulation cascade inducing hemostasis independently of factor VIII (F.VIII) or factor IX (RIX). Such an agent should be not only hemostatically active but also safe with respect to thromboembolic complications. Factor Vila (F.VIIa) becomes proteolytically active when complexed with tissue factor or other phopholipids minimizing the risk of inducing systemic activation of the coagulation system.

Keywords

Prothrombin Time Tissue Factor Disseminate Intravascular Coagulation Tranexamic Acid Disseminate Intravascular Coagulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    U. Hedner, W. Kisiel, Use of human factor Vila in treatment of two haemophilia A patients with high-titer inhibitors, J Clin Invest. 71: 1836 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    . U. Hedner, S. Bjoern, S.S. Bernvil, L. Tengborn, L. Stigendahl, Clinical experience with human plasma-derived factor Vila in patients with hemophilia A and high-titer inhibitors, Haemostasis. 19: 335 (1989).PubMedGoogle Scholar
  3. 3.
    F.S, Hagen, CL. Gray, P. O’Hara, FJ. Grant, G.C. Saari, R.G. Woodbury, CE. Hart, M. Insley, W. Kisiel, K. Kurachi, E.W. Davie, Characterization of a cDNA coding for human factor VII, Proc Nat’l Acad Sci USA. 83: 2413 (1986).Google Scholar
  4. 4.
    . L. Thim, S. Bjoern, M. Christensen, E.M. Nicolaisen, T. Lund-Hansen, AH. Pedersen, U. Hedner, Amino acid sequence and posttranslational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry. 27: 7785 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    U. Hedner, T. Lund-Hansen, D. Winther, Comparison of the effect of factor VII prepared from human plasma and recombinant Vila in vitro and in rabbits, Thromb Haemost. 58: 270a (1987).Google Scholar
  6. 6.
    U. Hedner, J. Ljungberg, T. Lund-Hansen, Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model, Blood and Fibrinol. 1: 145 (1990).Google Scholar
  7. 7.
    K.M. Brinkhous, U. Hedner, J.B. Garrís, V. Diness, M.S. Read, Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia, hemophilia B, and von Willebrand disease, Proc Natl Acad Sci USA. 86: 1382 (1989).PubMedCrossRefGoogle Scholar
  8. 8.
    . S.I. Rapaport, Inhibition of factor Vila/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibitory mechanism, Blood73: 359 (1989).PubMedGoogle Scholar
  9. U. Hedner, S. Schulman, K.A. Alberts, M. Blomback, H. Johnsson, S. Glazer, K. Pingel, Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet. ii: 193 (1988).Google Scholar
  10. 10.
    G.B. Macik, H. Hohneker, H. Roberts, A.M. Griffin, The use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a hemophilic patient with a high-titer inhibitor. Am J Hematology. 32: 232 (1989).CrossRefGoogle Scholar
  11. 11.
    S.A. Grupp, S. Glazer, D.A. Williams, Recalcitrant epistaxis in a hemophiliac with inhibitors: Experience with recombinant factor Vila. Blood 74(Suppl 1 ): 3901 (abstract no. 1489) (1989).Google Scholar
  12. 12.
    M.L. Schmidt, H.E. Smith, S. Gamerman, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa). Treatment for severe bleeding and surgical hemostasis in a factor-IX deficient patient with an inhibitor. Paper presented at a meeting of the Society for Pediatric Research, MA (1990).Google Scholar
  13. 13.
    A. Gringeri, E. Santagostino, P.M. Mannucci, Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody, Haemostasis. 21: 1 (1991).Google Scholar
  14. 14.
    . L. Tengborn, L. Stigendahl, P.O. Elfstrand, B. Kjellman, S. Glazer, Hemostatically effective treatment with recombinant factor Vila (rFVIIa) of a hemophiliac boy with newly developed inhibitors to factor VIII. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C., August 14 to 19 (1990).Google Scholar
  15. 15.
    M.L. Schmidt, H.E. Smith, S. Gamerman, D. DiMichele, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX deficient patient with an inhibitor, Br J Haematol. 78:460 (1991.)Google Scholar
  16. 16.
    U. Hedner, M. Feldstedt, S. Glazer, Recombinant FV1Ia in hemophilia treatment, in: Hemophilia and von Willebrands Disease in the 1990s, J.M. Lusher, CM. Kessler, eds., Elsevier Science Publishers B.V. (1991).Google Scholar
  17. 17.
    J. Ingerslev, M. Feldstedt, S. Sindet-Petersen, Control of hemostasis by recombinant factor Vila in a hemophilia A patient with inhibitors during major oral surgery. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C, August 14 to 19 (1990).Google Scholar
  18. 18.
    S.F. Stein, A. Duncan, D. Cutler, S. Glazer, Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor Vila. Abstract presented at the American Society of Hematology 32nd Annual Meeting, Boston, MA, November 28 to December 4 (1990).Google Scholar
  19. 19.
    U. Hedner, Factor Vila in the treatment of haemophilia, Blood Coagul Fibrinolysis. 1: 307 (1990).PubMedCrossRefGoogle Scholar
  20. 20.
    B.A. Bell, K. Birch, S. Glazer, Experience with recombinant factor Vila in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. Am J Pediatr Hematol Oncol. 15: 77 (1993).PubMedCrossRefGoogle Scholar
  21. 21.
    S. Schulman, A therapeutic alternative for haemophiliacs with inhibitors. Acta Pediatr. 81, paper 926 (1992).Google Scholar
  22. 22.
    J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Haemostatic efficacy of recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the XX International Congress of the World Federation of Hemophilia, Athens, Greece, October 12 to 17(1992).Google Scholar
  23. 23.
    J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Clinical experiences with recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the 3rd Bari International Conference on Factor VIII/von Willebrand Factor, Foggia, Italy, June 7 to 13 (1992).Google Scholar
  24. 24.
    M. Makris, Recombinant factor Vila: The UK experience. Abstract presented at the 24th Congress of the International Society of Hematology, London, UK, August 23 to 27 (1992).Google Scholar
  25. 25.
    U. Hedner, S. Glazer, Management of hemophilia patients with inhibitors, Hematol Oncol Clin North Am6: 1035 (1992).PubMedGoogle Scholar
  26. 26.
    M.L. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for muscle and soft tissue hemorrhage in factor VIII and IX-defìcient patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).Google Scholar
  27. 27.
    MX. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage (ICH) in hemophilia A patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).Google Scholar
  28. 28.
    D.B. Brettler, A.D. Forsberg, RH. Levine, et al, The use of porcine factor VIII concentrate (HyateiC) in the treatment of patients with inhibitor antibodies to factor FVIII, Arch Intern Med. 149: 1381 (1989).PubMedCrossRefGoogle Scholar
  29. 29.
    J.M. Lusher, et al., Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII, N Eng J Med. 303: 421 (1980).CrossRefGoogle Scholar
  30. 30.
    L.J.M. Sjamsoedin, et al., The effect of activated prothrombin-complex concentrate (Feiba) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor Vili. A double-blind clinical trial, N Engl J Med305: 717 (1981).PubMedCrossRefGoogle Scholar
  31. 31.
    J.M. Lusher, PM. Blatt, J.A. Penner, et al., Autoplex versus proplex: A controlied, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII, Blood62: 1135 (1983).PubMedGoogle Scholar
  32. 32.
    M. Hilgartner, L. Aledort, A. Andes, J.C. Gill, Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients, Transfusion30: 626 (1990)PubMedCrossRefGoogle Scholar
  33. 33.
    CK. Kasper, L. Boylen, N. Ewing, J.V. Luck, S.L. Dietrich, Hematologic management of hemophilia A for surgery, JAMA. 253: 1279 (1985).PubMedCrossRefGoogle Scholar
  34. 34.
    L. Johansen, D. Bucher, L.L. Hansen, H. Kastberg, CM. Lindley, P. Madsen, W.T. Sawyer, Relation between factor Vila coagulant activity and PT and between factor Vila coagulant activity and APTT in human plasma, Abstract presented at the XlVth Congress of the International Society on Thrombosis and Hemostasis, New York, USA, July 4 - 9 (1993).Google Scholar
  35. 35.
    D.S.C Telgt, B.G. Macik, D.M. McCord, D.M. Monroe, H.R. Roberts, Mechanism by which recombinant factor Vila shortens the aPTT: Activation of factor X in the absence of tissue factor, Thromb Res. 56:603(1989).PubMedCrossRefGoogle Scholar
  36. 36.
    I.M. Nilsson, U. Hedner, A. Ahlberg, et al.. Surgery of hemophiliacs-20 years’ experience, World J Surg. 1:55(1977).PubMedCrossRefGoogle Scholar
  37. 37.
    R.P.C. Rodgers, J. Levin, A critical reappraisal of the bleeding time, Semin Thromb Hemost. 16 No.1(1990).Google Scholar
  38. 38.
    H.J. Weiss, B. Lages, Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds, Blood629: 635 (1988).Google Scholar
  39. 39.
    U. Hedner, D. Bergqvist, J. Ljungberg, B. Nilsson, Haemostatic effect of factor Vila in thrombocytopenic rabbits, Blood. 66:1043(1985).Google Scholar
  40. 40.
    J. Kristensen, A. Killander, E. Hippe, C. Helleberg, J. Ellegaard, M. Holm, U. Hedner, Recombinant factor Vila (rFVIIa) reduces the bleeding time in patients with thrombocytopenia, Abstract submitted to The American Society of Hematology 35th Annual Meeting, St. Louis, USA, December 3–7 (1993).Google Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Steven Glazer
    • 1
  • Ulla Hedner
    • 1
  • Jorn F. Falch
    • 1
  1. 1.Novo Nordisk A/S Biopharmaceuticals DivisionGentofteDenmark

Personalised recommendations